SCHEMBL333393

SCHEMBL333393

CNC(=O)Cc1ccc(CO)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.49
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
POLB P06746 1/20 0.46
HTT P42858 1/20 0.46
HDAC4 P56524 1/20 0.45
TDP1 Q9NUW8 2/20 0.44
AOC2 O75106 1/20 0.43
HDAC8 Q9BY41 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HPGD P15428 4/20 0.42
GAA P10253 1/20 0.41
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41
ALDH1A1 P00352 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL171860 0.83 HPGD (0.59) LMNAPOLBMEN1KMT2AHPGD
SCHEMBL10569182 0.83 CA2 (0.56) LMNACA2POLBHTTHDAC4
SCHEMBL1972574 0.83 LMNA (0.68) LMNACA2POLBHTTHDAC4
SCHEMBL4475117 0.83 PLK1 (0.59) LMNAPOLBHTTHDAC4TDP1
SCHEMBL1632446 0.81 LMNA (0.51) LMNAPOLBHTTHDAC4TDP1
SCHEMBL9199667 0.81 LMNA (0.47) LMNAPOLBHTTHDAC4TDP1
SCHEMBL14394201 0.81 GLS (0.50) LMNAPOLBHTTHDAC4TDP1
SCHEMBL8135278 0.81 KLKB1 (0.52) LMNAPOLBHTTHDAC4TDP1
SCHEMBL3324450 0.81 KMT2A (0.59) LMNAHTTMEN1KMT2A
SCHEMBL1137228 0.81 GAA (0.63) LMNAHTTTDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 661 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230076173-A1 ANTIMICROBIAL MATRIX AND USES THEREOF FOR ELIMINATING MICROORGANISMS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2023-03-09 US claimed
EP-4100070-A1 ANTIMICROBIAL MATRIX AND USES THEREOF FOR ELIMINATING MICROORGANISMS Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) 2022-12-14 EP claimed
WO-2021156877-A1 ANTIMICROBIAL MATRIX AND USES THEREOF FOR ELIMINATING MICROORGANISMS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2021-08-12 WO claimed
US-20050261475-A1 Solid-phase capture-release-tag methods for phosphoproteomic analyses HARVARD MEDICAL SCHOOL (US) 2005-11-24 US claimed
EP-0418617-B1 Method for preparing human osteocalcin MITSUBISHI PETROCHEMICAL CO (JP) 1994-11-09 EP claimed
US-5164483-A Bone disorder diagnosis MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1992-11-17 US claimed
EP-0418617-A1 Method for preparing human osteocalcin MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1991-03-27 EP claimed
US-4293455-A N.sup.α -Desacetylthymosinα1 and process ROCKEFELLER UNIVERSITY (US) 1981-10-06 US claimed
JP-1296996-A None JP disclosed
JP-4149197-A None JP disclosed
JP-63190900-A None JP disclosed
EP-4626955-A2 POLY(ETHYLENE GLYCOL)-POLYOXAZOLINE (PEOZ) COPOLYMERS FOR SOLUBILIZING DRUGS, DYES, AND BIOPHARMACEUTICALS Becton, Dickinson and Company (US) 2025-10-08 EP disclosed
CN-120051508-A Polyethylene glycol-Polyoxazoline (PEOZ) copolymers for dissolving drugs, dyes and biopharmaceuticals 贝克顿·迪金森公司 2025-05-27 CN disclosed
WO-2024143052-A1 PEPTIDE SYNTHESIS METHOD 学校法人神戸学院 2024-07-04 WO disclosed
US-4824937-A Synthetic natriuretic peptides 501 Advanced Peptide Development, Ltd. (GB) 1989-04-25 US disclosed
WO-1989000166-A2 GROWTH HORMONE RELATED PEPTIDE PEPTIDE TECHNOLOGY LTD (AU) 1989-01-12 WO disclosed
US-4769445-A Process for the solid phase synthesis of peptides which contain sulfated tyrosine PENNWALT CORPORATION (US) 1988-09-06 US disclosed
JP-S63190900-A NOVEL PEPTIDE KAJI AKIRA 1988-08-08 JP disclosed
EP-0246795-A2 Synthetic natriuretic peptides ADVANCED PEPTIDE DEVELOPMENT LIMITED (GB) 1987-11-25 EP disclosed
EP-0161468-A2 Process for the solid phase synthesis of peptides which contain sulfated tyrosine PENNWALT CORPORATION (US) 1985-11-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261475-A1 Solid-phase capture-release-tag methods for phosphoproteomic analyses PTMS, CHAMP1, ACP1 LMNA 2867/4885CA1 2212/4885CA2 2481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.